QA108 Phase III Study in Subjects With Intermediate AMD

Summary

This is a phase III randomized, double-masked, placebo-controlled, multicenter study. To evaluate the efficacy and safety of QA108 granules in the treatment of intermediate age-related macular degeneration.

Timeline

Start

2025-07-08

Primary completion

2027-03-01

Completion

2027-06-30

Drugs

Indications